Syndax Pharmaceuticals (SNDX)
Markets targeted therapies for acute leukemias and chronic graft-versus-host disease.
$17.27
vs last close−0.92 (−5.06%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 121.97% | 108.92M shares | |
|---|---|---|---|
| 254 holders · as of Jun 30, 2026 | |||
| Insiders | 1.80% | 1.60M shares | |
| 11 holders · as of Jul 9, 2026 | |||
| Adds to | 123.77% | ||
89.30M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 123.77%; nothing is left for Other.
13F, as of Jun 30, 2026
254 holders · 108.92M shares · 40 new positions · 134 increased · 78 reduced · 42 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 9.02M | 10.10% | +765.6K | Aug 7, 2026 |
| Kynam Capital Management, LP | 8.05M | 9.02% | 0 | Aug 14, 2026 |
| Goldman Sachs Group Inc | 5.86M | 6.56% | +864.5K | Aug 14, 2026 |
| State Street Corp | 5.66M | 6.34% | +1.23M | Aug 7, 2026 |
| Bank of America Corp /DE/ | 4.05M | 4.53% | −204.7K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 3.93M | 4.40% | +105.3K | Aug 13, 2026 |
| Deerfield Management Company, L.P. (Series C) | 3.78M | 4.23% | 0 | Aug 14, 2026 |
| Eversept Partners, LP | 2.80M | 3.13% | −87.4K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Kynam Capital Management, LP | 9.98% | 8.52M | 13G | Feb 14, 2025 |
| BlackRock, Inc. | 7.80% | 6.74M | 13G | Apr 17, 2025 |
| The Goldman Sachs Group, Inc. | 6.50% | 5.58M | 13G | Aug 13, 2025 |
| State Street Corporation | 6.40% | 5.66M | 13G | Aug 7, 2026 |
| Vanguard Capital Management | 5.05% | 4.46M | 13G | Apr 30, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 8, 2026 | Michael A. Metzgerdirector, officer: Chief Executive Officer | Sale | 32,375 | $24.24 | 484,843 |
| Jun 12, 2026 | Nicholas A.J. Botwoodofficer: Head of R&D, CMO | Sale | 31,235 | $18.14 | 60,885 |
| Jun 11, 2026 | Nicholas A.J. Botwoodofficer: Head of R&D, CMO | Sale | 34,280 | $18.00 | 60,885 |
| Jun 1, 2026 | Michael A. Metzgerdirector, officer: Chief Executive Officer | Sale | 6,847 | $18.99 | 484,843 |
| Jun 1, 2026 | Keith A. Goldanofficer: Chief Financial Officer | Sale | 1,177 | $18.99 | 139,252 |
| Feb 9, 2026 | Keith A. Goldanofficer: Chief Financial Officer | Sale | 3,410 | $21.03 | 140,429 |
| Feb 9, 2026 | Michael A. Metzgerdirector, officer: Chief Executive Officer | Sale | 17,159 | $21.03 | 491,690 |
| Feb 6, 2026 | Keith A. Goldanofficer: Chief Financial Officer | Sale | 2,082 | $20.62 | 143,839 |
| Feb 6, 2026 | Michael A. Metzgerdirector, officer: Chief Executive Officer | Sale | 7,412 | $20.62 | 508,849 |
House and Senate disclosures
Not reported.